Fusion polypeptides for metabolic disorders
AssigneeBeijing Ql Biopharmaceutical Co., Lt
InventorsYuanyuan Zhang, Bo Wu, Wei Guo, Xiaona Dong, Yuying Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. The present disclosure further provides conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
Claims23
A polypeptide, comprising, in a direction from N terminus to C terminus:
- a first fragment comprising a nanobody domain capable of binding to serum albumin;
- and
- a second fragment comprising a biologically active FGF21 domain, wherein the FGF21 domain comprises the amino acid sequence of SEQ ID NOs:
- 6-10, 13 and 92;
- wherein:
- the first fragment and the second fragment are connected via a first linker;
- the polypeptide further comprising, over an N-terminus of the first fragment, a third fragment comprising a biologically active peptide, or a fragment thereof, of GLP-1,
- wherein:
- the first fragment and the third fragment are connected via a second linker.
A polypeptide comprising an amino acid sequence selected from SEQ ID NOS:
- 74, 81-83, 85 and 96-97, wherein the polypeptide comprises a conjugatable cysteine residue, the polypeptide is conjugated with a synthetic chemical moiety at the conjugatable cysteine residue, the conjugatable cysteine residue is at position 171, and the synthetic chemical moiety has the below structure:
A polypeptide comprising an amino acid sequence selected from SEQ ID NOS:
- 70, 75, 79-80, 95, 98, and 108-109.
Dependencies are inferred from the claim text.